{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:45:57Z","timestamp":1764240357886,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013385","name":"National Science and Technology Program during the Twelfth Five-year Plan Period","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijid.2020.05.041","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T04:21:48Z","timestamp":1590726108000},"page":"562-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs"],"prefix":"10.1016","volume":"96","author":[{"given":"Xuli","family":"Bao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yachao","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijid.2020.05.041_bib0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"Bourliere","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ijid.2020.05.041_bib0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/1751-2980.12065","article-title":"Extended treatment with peginterferon alpha-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg sero-conversion","volume":"14","author":"Cao","year":"2013","journal-title":"J Digest Dis"},{"issue":"11\u201312","key":"10.1016\/j.ijid.2020.05.041_bib0015","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2036.2010.04474.x","article-title":"Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B[J]","volume":"32","author":"Chan","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ijid.2020.05.041_bib0020","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/infdis\/jix024","article-title":"Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos(t)ide analogue\uff1aa randomized, contro1led trial(PEGON)[J]","volume":"215","author":"Chi","year":"2017","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.ijid.2020.05.041_bib0025","first-page":"888","article-title":"The guideline of prevention and treatment for chronic hepatitis B:a 2015 update","volume":"23","author":"Chinese Society of Hepatology","year":"2015","journal-title":"Chin J Hepatol"},{"issue":"2","key":"10.1016\/j.ijid.2020.05.041_bib0030","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2020.05.041_bib0035","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0168-8278(11)60071-8","article-title":"69 NEPTUNE Study\uff1aOn-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients","volume":"54","author":"Gene","year":"2011","journal-title":"J Hepatol"},{"issue":"9454","key":"10.1016\/j.ijid.2020.05.041_bib0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B\uff1aa randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ijid.2020.05.041_bib0045","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijid.2020.05.041_bib0050","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ijid.2020.05.041_bib0055","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"issue":"9859","key":"10.1016\/j.ijid.2020.05.041_bib0060","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010\uff1aa systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"6176","key":"10.1016\/j.ijid.2020.05.041_bib0065","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and non-hepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2020.05.041_bib0070","first-page":"718A","article-title":"In patients with HBeAg negative chronic hepatitis B, HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance up to 4 years post-treatment","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ijid.2020.05.041_bib0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ijid.2020.05.041_bib0080","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop\uff1aa strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ijid.2020.05.041_bib0085","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B\uff1aa randomised open-label trial(OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2020.05.041_bib0090","first-page":"S43","article-title":"Switching to PegIFN\u03b1-2a in NUC treated CHB patients(NEW SWITCH Study)\uff1acomparison 48 and 96 weeks","volume":"10","author":"Ren","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.ijid.2020.05.041_bib0095","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ijid.2020.05.041_bib0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220303489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220303489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:55:16Z","timestamp":1761119716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971220303489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"alternative-id":["S1201971220303489"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.05.041","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}